BioLineRx reported a transformative quarter driven by the establishment of a joint venture with Hemispherian to develop GLIX1, a promising treatment for glioblastoma, while maintaining a robust pipeline with significant potential in multiple cancer indications.

• Established a joint venture with Hemispherian to develop GLIX1 for glioblastoma, enhancing clinical and regulatory capabilities.
• GLIX1 has a unique mechanism targeting DNA damage response, with potential applications in various cancer types, supported by impressive preclinical results.
• Company anticipates initiating a Phase I/IIa clinical trial for GLIX1 in early 2026, with data expected in 2027.
• A recently granted patent broadens GLIX1’s protection until at least 2040, strengthening its market position against competitors.
• The addressable market for GLIX1 targeting glioblastoma alone exceeds $3.7 billion in the U.S. and Europe, reflecting significant growth potential.